Celmatix

The firm recently won $4.5 million as well as approval for its Fertilome test from New York state, though some have questioned the test's clinical utility.

The award is one of 121 for projects in New York City this year, totaling $64.8 million.

The firm has secured NYS approval for its sequencing-based 32-gene Fertilome assay, which it originally launched in January. 

The companies will recruit and track a cohort of women to study environmental, genetic, and lifestyle factors that may contribute to fertility outcomes.

Fertility Genetics

Celmatix's Fertilome test aims to give women genetic insight into their fertility.

The company's new blood-based test is the first clinical test offering that the company will be offering at its New York-based CLIA laboratory.

They will work to accelerate the launch of Celmatix's infertility genetics tests and develop early screening tests for declining ovarian function.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.